Efficacy and tolerability of anti-tuberculotic chemotherapy in patients with newly diagnosed cavitary infiltrative pulmonary tuberculosis and a high risk of drug resistance in prisons

Abstract

Summary. In penitentiary hospitals, patients with infiltrative pulmonary tuberculosis and cavitation not having HIV infection were treated with combined antituberculosis therapy including Lomekomb. After 3 months of treatment, sputum culture conversion was observed in 73.5 % of patients and cavity closure in 32.4 %. Adverse events were seen in 97.1 % of cases, all of them were reversible. The most frequent adverse events were combined toxic and allergic reactions (67.6 % of patients) followed by toxic reactions (20.6 %) and allergic reactions (8.8 %) alone. Urticaria was observed in 17.6 % of patients, blood eosinophilia in 73.5 %, and elevated transaminases in 82.4 %.